Production (Stage)
Arcutis Biotherapeutics, Inc.
ARQT
$13.98
$0.322.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.95% | 54.98% | |||
| Total Other Revenue | 0.00% | -- | |||
| Total Revenue | -7.73% | 59.45% | |||
| Cost of Revenue | 27.88% | 25.48% | |||
| Gross Profit | -11.54% | 64.21% | |||
| SG&A Expenses | 11.10% | -2.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.41% | -5.76% | |||
| Operating Income | -221.40% | 80.46% | |||
| Income Before Tax | -136.80% | 74.81% | |||
| Income Tax Expenses | -13.62% | -- | |||
| Earnings from Continuing Operations | -132.30% | 74.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -132.30% | 74.03% | |||
| EBIT | -221.40% | 80.46% | |||
| EBITDA | -198.26% | 80.94% | |||
| EPS Basic | -130.09% | 74.15% | |||
| Normalized Basic EPS | -134.54% | 74.92% | |||
| EPS Diluted | -130.09% | 74.15% | |||
| Normalized Diluted EPS | -134.54% | 74.92% | |||
| Average Basic Shares Outstanding | 0.90% | 0.50% | |||
| Average Diluted Shares Outstanding | 0.90% | 0.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||